Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zions Bancorporation due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Zions Bancorporation securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the alleged misleading information [2]. Group 2: Financial Impact and Company Disclosure - On October 15, 2025, Zions Bancorporation announced a $50 million charge-off for a loan due to misrepresentations and contractual defaults by borrowers [3]. - Following this announcement, Zions Bancorporation's common stock experienced a decline of 13.14% on October 16, 2025 [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [5]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Gauzy Ltd. for allegedly misleading investors regarding its business operations and financial stability [1][2]. Group 1: Allegations - The lawsuit claims that Gauzy's French subsidiaries lacked the financial means to meet their debts as they became due [3]. - It is alleged that insolvency proceedings were likely to commence due to the financial issues faced by these subsidiaries [3]. - The lawsuit also states that a potential default under Gauzy's existing senior secured debt facilities was substantially likely as a result of these issues [3]. - Positive statements made by Gauzy regarding its business operations and prospects were deemed materially misleading and lacked a reasonable basis [3]. Group 2: Legal Proceedings - Shareholders wishing to serve as lead plaintiffs must file their motions with the court by February 6, 2026 [4]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [4]. Group 3: Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Investors who purchased America's Car-Mart securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Performance and Market Reaction - On September 4, 2025, America's Car-Mart reported a first-quarter loss of 69 cents per share, compared to a net loss of 15 cents per share in the same period the previous year [3]. - Following the release of these results, America's Car-Mart's stock experienced a significant decline of 18.2% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1] Group 1: Investigation Details - The investigation is prompted by a press release from Alvotech on November 2, 2025, regarding the status of its Biologics License Application (BLA) for AVT05, which received a complete response letter (CRL) from the FDA [3] - The CRL indicated that certain deficiencies identified during the FDA's pre-license inspection of Alvotech's Reykjavik manufacturing facility must be resolved before the BLA can be approved [3] - Following the announcement, Alvotech's stock price dropped by 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3] Group 2: Class Action Information - Shareholders who purchased Alvotech securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2] - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - To serve as lead plaintiff, individuals must file with the Court by December 30, 2025, acting on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4]. Group 3: Case Allegations - The lawsuit alleges that Synopsys' management made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [5]. - Specific claims include the negative impact of Synopsys' focus on artificial intelligence customers on its Design IP business, leading to poor financial results and misleading positive statements from management [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Issues - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Investors who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Freeport-McMoRan Inc. securities between February 15, 2022, and September 24, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Freeport-McMoRan securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 12, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Freeport-McMoRan made false and misleading statements regarding safety measures at the Grasberg Block Cave mine in Indonesia, which posed a heightened risk to workers [5]. - It is claimed that the lack of proper safety precautions led to undisclosed regulatory, litigation, and reputational risks, resulting in materially false statements about the company's business and operations [5].

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. (NASDAQ: CPTN) common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased or sold Cepton common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations during the Class Period [5]. - Specific allegations include the failure to disclose a credible third-party bid valuing Cepton at more than double the Koito Acquisition, and the Board's lack of meaningful exploration of this offer [5]. - As a result, shareholders were deprived of the opportunity to make an informed decision regarding the Koito Acquisition [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Alvotech on November 2, 2025, which announced that the U.S. FDA issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, indicating deficiencies that must be resolved before approval [3]. - Following the announcement of the CRL, Alvotech's stock price experienced a significant decline, falling 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3]. Group 2: Class Action Information - Investors who purchased Alvotech securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested investors can join the prospective class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Stride, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Stride securities is from October 22, 2024, to October 28, 2025, and the lead plaintiff deadline is January 12, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]. Group 3: Allegations Against Stride, Inc. - The lawsuit alleges that Stride made misleading statements regarding its products and services to educational institutions during the Class Period [4]. - Stride is accused of inflating enrollment numbers, excessively cutting staff costs, ignoring compliance requirements, and losing enrollments, which led to investor damages when the truth was revealed [4].